Aguracingene cadoparvovec (MeiraGTx)

N/A

Report date: 2025/07/01 15:17:12

Base Information

Drug NameAguracingene cadoparvovec (MeiraGTx)
Drug Alias NameAAV2/8-hG1.7p.coCNGA3AAV-CNGA3CNGA3-gene-therapy-AGTCRecombinant-adeno-associated-virus-vector-expressing-GNGAA-003
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV8 vector
Mechanisms of ActionCyclic nucleotide-gated cation channel alpha-3 stimulants
TargetsCyclic nucleotide-gated cation channel alpha-3
Therapy Area/IndicationsColor Vision Defects
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMeiragtx Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMeiragtx Uk Ii LtdJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsColor Vision Defects
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A